Rates and Predictors of PVD in Comprehensive Ophthalmic Practice
Endophthalmitis Risk of Sequential Bilateral Cataract Surgery
Achieving Target IOP Slows VF Decline
Retinal Atrophy After Luxturna Injections for LCA
Sequential Versus Simultaneous Patching for Unilateral Amblyopia
Relationship of Vision to Retinal Fluid in Ranibizumab-Treated Neovascular AMD
Lapses in Care for PDR After Anti-VEGF Tx
Residency Applications and Implicit Bias
IOP-Related Events After IVIs for Macular Edema in SCORE2
Phaco-ECP for POAG: Results at Three Years
Cost-Utility Comparison of RRD Interventions
Advertisement
Explore TEPEZZA® (teprotumumab-trbw) now for your patients with this serious, progressive disease.
TEPEZZA is a trademark owned by or licensed to Horizon.© 2022 Horizon Therapeutics plc P-TEP-US-00805 12/22